Global advances in integrative medicine and health

Healthcare Providers' Views on Psychedelic Therapies in Medical Care: Offering Assisted Dying but Not Psychedelic Prescriptions

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Healthcare providers' perspectives on psychedelic-assisted therapy (PAT) in Canada are underexplored.

  • Attitudes toward ketamine, psilocybin, and MDMA among healthcare providers may vary significantly.
  • Systemic factors, such as regulatory frameworks, could impact the implementation of psychedelic therapies.
  • Ethical considerations are associated with the acceptance of PAT in palliative and oncology care contexts.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

0 of 6
authors report competing interests
6 report none
PubMed
No competing interests reported.

Related papers

Dec '21
Palliative care providers' views on deep emotional suffering and using psychedelics for treatment
top 20% journal
cited by 37 papers
journal article
Sep '25
Patient Views on Using Psychedelic Therapy to Help Cancer-Related Emotional Challenges
top 30% journal
cited by 1 paper
journal article
Jun '26
Early experiences using psilocybin therapy to support cancer patients receiving palliative care
top 30% journal
journal article
Sep '24
Psychedelic-assisted therapy for anxiety, depression, and distress in people with serious illnesses
cited by 25 papers
systematic review
Jul '26
Australian healthcare professionals’ views on using psilocybin to ease cancer-related existential distress
top 5% journal
journal article
Nov '25
Ethical issues in using therapeutic touch during psychedelic-assisted therapy based on researchers’ views and experiences
top 20% journal
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the psychedelic science brief

issue #60
Psilocybin rewires synapses in one brain layer but hallucinations come from somewhere else
yesterday7 studies
issue #59
Oregon and Colorado psilocybin clients saw 49% drop in depression scores after just one session
1 week ago7 studies
issue #58
Psilocybin doesn't change how much neurons fire — it changes how they fire
2 weeks ago7 studies
issue #57
Psilocybin cut depression scores in bipolar II patients without triggering mania
3 weeks ago7 studies
issue #56
Scientists designed psychedelics that skip the heart-risk receptor entirely
4 weeks ago7 studies
issue #55
Early psychedelic trials found no lasting benefits — and the methods were better than we thought
5 weeks ago7 studies
issue #54
Two psilocybin doses before chemo prevented nerve damage in animal models — without hurting tumor treatment
6 weeks ago7 studies
issue #53
One psilocybin session held antidepressant effects for 52 weeks in a new follow-up study
7 weeks ago7 studies
issue #52
Psilocybin didn't create disorder in the brain — it created a different kind of order
8 weeks ago7 studies
issue #51
Psilocybin worked for treatment-resistant depression in real Swiss clinics — not just controlled trials
9 weeks ago7 studies
explore the archive
See more issues from the psychedelic science brief